- Home
- Publications
- Publication Search
- Publication Details
Title
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Authors
Keywords
chronic kidney disease, eplerenone, finerenone, mineralocorticoid receptor, spironolactone
Journal
Kidney International Reports
Volume 6, Issue 9, Pages 2281-2291
Publisher
Elsevier BV
Online
2021-06-10
DOI
10.1016/j.ekir.2021.05.027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda
- (2020) Panagiotis I. Georgianos et al. CURRENT HYPERTENSION REPORTS
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment
- (2019) Roland Heinig et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
- (2019) Fabian Hammer et al. KIDNEY INTERNATIONAL
- The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
- (2019) Daniel Lavall et al. BIOCHEMICAL PHARMACOLOGY
- Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
- (2019) Nelleke Snelder et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo
- (2018) Roland Heinig et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
- (2018) Gianluigi Savarese et al. EUROPEAN JOURNAL OF HEART FAILURE
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Revisiting RAAS blockade in CKD with newer potassium-binding drugs
- (2018) Panagiotis I. Georgianos et al. KIDNEY INTERNATIONAL
- Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study
- (2018) Rajiv Agarwal et al. AMERICAN JOURNAL OF NEPHROLOGY
- Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
- (2018) Michael Gerisch et al. DRUG METABOLISM AND DISPOSITION
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
- (2018) Robert M. Carey et al. HYPERTENSION
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. JOURNAL OF HYPERTENSION
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- Aldosterone Target NGAL (Neutrophil Gelatinase–Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB PathwayNovelty and Significance
- (2017) Ernesto Martínez-Martínez et al. HYPERTENSION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Diabetes with early kidney involvement may shorten life expectancy by 16 years
- (2017) Chi Pang Wen et al. KIDNEY INTERNATIONAL
- Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study
- (2017) Reimar W Thomsen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis
- (2016) Kevin Quach et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial InfarctionNovelty and Significance
- (2016) Alexandre Gueret et al. HYPERTENSION
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease
- (2015) George Thomas et al. HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
- (2015) Frank Y. Ma et al. PLoS One
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Prevalence of Apparent Treatment-Resistant Hypertension among Individuals with CKD
- (2013) R. M. Tanner et al. Clinical Journal of the American Society of Nephrology
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms
- (2012) Linda Shavit et al. KIDNEY INTERNATIONAL
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now